NCT05190107

Brief Summary

Background: Social isolation secondary to the pandemic can predispose the population to mental health issues in the future, especially teenagers. The Depression, Anxiety, and Stress Scale (DASS) is a valuable self-report scale since it may be used to screen for anxiety, depression, and stress in one questionnaire. In the last years, it has been observed effective in detecting these symptoms in teenagers. Aims: Identify the prevalence of depression, anxiety, and stress in high school students during the COVID-19 pandemic This is an observational cross-sectional study. For this study, the validated Spanish version of DASS-21 will be used. Qualitative variables will be evaluated through central tendencies, such as mean, standard deviation, and frequencies. The inferential analysis of categorical variables will be performed using the chi-squared test, analysis of variance (ANOVA), or Kruskal Wallis test as appropriate. For quantitative variables, Student's t-test or Mann Whitney U test will be performed depending on their distribution.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,112

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2021

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2021

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

December 10, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 10, 2021

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 13, 2022

Completed
Last Updated

January 13, 2022

Status Verified

December 1, 2021

Enrollment Period

6 months

First QC Date

December 10, 2021

Last Update Submit

December 28, 2021

Conditions

Outcome Measures

Primary Outcomes (3)

  • Depression Score

    the Depression, Anxiety and Stress Scale 21 (DASS-21) is an inventory that will be used to identify the presence and intensity of depressive, anxiety and stress. For depression the cutoff scores are: Normal: 0-9, Mild: 10-12, Moderate:13-20, Severe: 21-27, and Extremely severe: 28-42.

    Baseline

  • Anxiety Score

    the Depression, Anxiety and Stress Scale 21 (DASS-21) is an inventory that will be used to identify the presence and intensity of depressive, anxiety and stress. For anxiety the cutoff scores are: Normal: 0-6, Mild: 7-9, Moderate: 10-14, Severe:15-19, and Extremely severe: 20-42.

    Baseline

  • Stress Score

    the Depression, Anxiety and Stress Scale 21 (DASS-21) is an inventory that will be used to identify the presence and intensity of depressive, anxiety and stress. For stress the cutoff scores are: Normal: 0-10, Mild:11-18, Moderate:19-26, Severe: 27-34, and Extremely severe: 35-42.

    Baseline

Interventions

DASS-21 scaleDIAGNOSTIC_TEST

Each construct consists of 7 questions. The participants must select the answer that better represents their feelings over the last week in each scenario. Each question has a Likert scale of 4 options where 0 represents "did not apply to me" to 3 "applied to me very much.

Eligibility Criteria

Age14 Years - 22 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Adolescents from 14 to 22 years old with an average age of 16 years are high school students.

You may qualify if:

  • Adolescents from 14 to 22 years old.
  • That they voluntarily agree to participate, and consent.

You may not qualify if:

  • Adolescents with depression, anxiety, and stress disorders previously detected
  • Patients in psychiatric treatment for depression, anxiety, or stress.
  • Participants who don´t consent to participate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centro Médico Nacional de Occidente

Guadalajara, Jalisco, 44329, Mexico

Location

MeSH Terms

Conditions

DepressionAnxiety Disorders

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehaviorMental Disorders

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator D

Study Record Dates

First Submitted

December 10, 2021

First Posted

January 13, 2022

Study Start

May 1, 2021

Primary Completion

November 1, 2021

Study Completion

December 10, 2021

Last Updated

January 13, 2022

Record last verified: 2021-12

Locations